Starting diabetic macular edema treatment with bevacizumab and switching to aflibercept if needed offers nearly identical vision outcomes to aflibercept monotherapy, but at a far lower cost. A cost-effectiveness analysis from the DRCR Retina Network found that aflibercept’s slight advantage in quality-adjusted life years does not justify its high price, which exceeds $800,000 per QALY gained.